Cardiovascular risk factors and immunosuppressive regimen after liver transplantation.
Cardiovascular and metabolic diseases represent important long-term complications after liver transplantation (LT), impairing long-term and disease-free survivals. A few mechanisms underlie the development of those complications, but the role of immunosuppressive drugs is major. Although several patients develop temporary metabolic diseases, which normalize after a short postoperative period and do not need long-term drug therapy, the incidences of de novo long-lasting arterial hypertension, hyperlipidemia, and diabetes mellitus are high during the first year after LT. The aim of this retrospective study was to evaluate new-onset arterial hypertension, hyperlipidemia, or diabetes among 100 LT patients at a single institution. We used chi-square statistical analysis to compare incidences during tacrolimus versus cyclosporine therapy. Hypertension did not seem to be more strongly related to tacrolimus than to cyclosporine, nor did diabetes, whereas there was a difference for the development of hyperlipidemia.
Rossetto
A
A
Department of Surgery and Transplantation, University Hospital, Udine, Italy. rossettoannaar@libero.it
Bitetto
D
D
Bresadola
V
V
Lorenzin
D
D
Baccarani
U
U
De Anna
D
D
Bresadola
F
F
Adani
G L
GL
D000959:Antihypertensive Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000453:epidemiology*; D003920:Diabetes Mellitus / Q000139:chemically induced / Q000188:drug therapy / Q000453:epidemiology; D018572:Disease-Free Survival; D004359:Drug Therapy, Combination / Q000009:adverse effects; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced / Q000188:drug therapy / Q000453:epidemiology; D006973:Hypertension / Q000139:chemically induced / Q000188:drug therapy / Q000453:epidemiology; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000009:adverse effects / Q000276:immunology*; D011183:Postoperative Complications / Q000139:chemically induced / Q000453:epidemiology; D012189:Retrospective Studies; D012307:Risk Factors
D000959:Antihypertensive Agents; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D007166:Immunosuppressive Agents